SCHEMBL964478

SCHEMBL964478

NS(=O)(=O)c1cccc(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.70
CA1 P00915 10/20 0.70
CA9 Q16790 7/20 0.59
CA12 O43570 6/20 0.59
CA14 Q9ULX7 5/20 0.59
CA4 P22748 4/20 0.59
CA5A P35218 4/20 0.54
CA7 P43166 4/20 0.54
CA6 P23280 3/20 0.54
CA13 Q8N1Q1 3/20 0.54
CA5B Q9Y2D0 3/20 0.54
CA3 P07451 2/20 0.54
PLA2G7 Q13093 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PGR P06401 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 1/20 0.51
MAOB P27338 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium SCHEMBL8054963 0.98 CA2 (0.67) CA2CA1CA9CA12CA14
SCHEMBL8054962 0.98 CA2 (0.67) CA2CA1CA9CA12CA14
SCHEMBL2398133 0.83 CA2 (1.00) CA2CA1CA9CA12CA14
SCHEMBL31435391 0.81 AKR1B1 (0.56) MEN1KMT2AALDH1A1PGRMMP2
SCHEMBL2199161 0.81 AKR1B1 (0.56) MEN1KMT2AALDH1A1PGRMMP2
SCHEMBL29960292 0.79 ALDH1A1 (0.59) MEN1KMT2AALDH1A1PGRMMP2
SCHEMBL29422524 0.79 ALDH1A1 (0.54) MEN1KMT2AALDH1A1PGRMMP2
SCHEMBL294451 0.79 ALDH1A1 (0.59) MEN1KMT2AALDH1A1PGRMMP2
SCHEMBL294450 0.79 PGR (0.53) MEN1KMT2AALDH1A1PGRMAPT
SCHEMBL8477676 0.79 ALDH1A1 (0.59) MEN1KMT2AALDH1A1PGRMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024115549-A1 ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-06 WO claimed
CN-114614058-B Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2024-05-07 CN claimed
CN-114432903-B Composite membrane with acid resistance and preparation method and application thereof 中国石油化工股份有限公司 2023-03-14 CN claimed
CN-114614058-A Thin-layer composite proton exchange membrane and preparation method and application thereof 中国石油化工股份有限公司 2022-06-10 CN claimed
CN-114432903-A Composite membrane with acid resistance and preparation method and application thereof 中国石油化工股份有限公司 2022-05-06 CN claimed
CN-112552214-A Production process for improving quality of sulfonyl isocyanate 安徽广信农化股份有限公司 2021-03-26 CN claimed
US-20150322094-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2015-11-12 US claimed
EP-2892343-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS Bayer CropScience AG (DE) 2015-07-15 EP claimed
WO-2014037349-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS BAYER CROPSCIENCE AG (DE) 2014-03-13 WO claimed
CN-103339132-A Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi YOUAI CO LTD 2013-10-02 CN claimed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP claimed
US-6313119-B1 VITRONECTIN RECEPTOR ANTAGONISTS ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-11-06 US claimed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US claimed
US-6291514-B1 Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-09-18 US claimed
WO-2001060814-A2 PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS SUGEN, INC. (US) 2001-08-23 WO claimed
EP-1054886-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-11-29 EP claimed
EP-1049677-A1 NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION Aventis Pharma Deutschland GmbH (DE) 2000-11-08 EP claimed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO claimed
WO-1999040088-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-08-12 WO claimed
WO-1999037621-A1 NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322094-A1 USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS CAT, HSF1, HPD CA2 341/4885CA1 1091/4885CA9 1495/4885
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 CA2 2597/4885CA1 2080/4885CA9 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.